Literature DB >> 32148190

Use of Benefit Enhancement Strategies among 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) Users: Associations with Mystical, Challenging, and Enduring Effects.

Rafael L Lancelotta1,2, Alan K Davis3,4.   

Abstract

5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) is a potent, fast-acting psychedelic. Anecdotal reports from 5-MeO-DMT users suggest that they employ a variety of benefit enhancement (BE) strategies aimed to increase positive effects and decrease any potential challenging effects of the substance, but no empirical study has investigated this claim. We examined the prevalence of BE strategy use using secondary data from a survey of 5-MeO-DMT users (n = 515; Mage = 35.4, SD = 11.7; Male = 79%; White/Caucasian = 86%). Results indicated that BE strategy use was common in this sample. As a secondary aim, we assessed whether the use of BE strategies was associated with acute subjective (i.e., mystical-type, challenging) and persisting effects of 5-MeO-DMT among a subset of respondents who reported using 5-MeO-DMT once in their lifetime (n = 116). Results showed that the use of several BE strategies were associated with significantly more intense mystical-type effects and enduring beliefs about the personal meaning and spiritual significance of their experience, and some BE strategies were associated with less intense or challenging experiences. Data suggests that BE strategies are commonly used, and that the use of BE strategies may be associated with increases in positive mystical-type and enduring effects. The causal influence of BE strategies on acute/persisting effects of 5-MeO-DMT should be examined in longitudinal research.

Entities:  

Keywords:  5-MeO-DMT; benefit enhancement; mystical-type experience; tryptamine

Year:  2020        PMID: 32148190      PMCID: PMC7415524          DOI: 10.1080/02791072.2020.1737763

Source DB:  PubMed          Journal:  J Psychoactive Drugs        ISSN: 0279-1072


  33 in total

1.  Prevalence and epidemiological associates of novel psychedelic use in the United States adult population.

Authors:  James D Sexton; Michael S Crawford; Noah W Sweat; Allyson Varley; Emma E Green; Peter S Hendricks
Journal:  J Psychopharmacol       Date:  2019-02-28       Impact factor: 4.153

2.  Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction.

Authors:  Albert Garcia-Romeu; Roland R Griffiths; Matthew W Johnson
Journal:  Curr Drug Abuse Rev       Date:  2014

3.  Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects.

Authors:  Roland R Griffiths; Matthew W Johnson; William A Richards; Brian D Richards; Una McCann; Robert Jesse
Journal:  Psychopharmacology (Berl)       Date:  2011-06-15       Impact factor: 4.530

4.  Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance.

Authors:  R R Griffiths; W A Richards; U McCann; R Jesse
Journal:  Psychopharmacology (Berl)       Date:  2006-07-07       Impact factor: 4.530

5.  5-Methoxy-N,N-dimethyltryptamine: behavioral and toxicological effects in animals.

Authors:  J C Gillin; J Tinklenberg; D M Stoff; R Stillman; J S Shortlidge; R J Wyatt
Journal:  Biol Psychiatry       Date:  1976-06       Impact factor: 13.382

Review 6.  Fifteen years of study of psychoactive snuffs of South America: 1967-1982--a review.

Authors:  R E Schultes
Journal:  J Ethnopharmacol       Date:  1984-06       Impact factor: 4.360

Review 7.  Potential Therapeutic Effects of Psilocybin.

Authors:  Matthew W Johnson; Roland R Griffiths
Journal:  Neurotherapeutics       Date:  2017-07       Impact factor: 7.620

8.  Dimethyltryptamine (DMT): prevalence, user characteristics and abuse liability in a large global sample.

Authors:  Adam R Winstock; Stephen Kaar; Rohan Borschmann
Journal:  J Psychopharmacol       Date:  2013-11-27       Impact factor: 4.153

Review 9.  Bufo alvarius: a potent hallucinogen of animal origin.

Authors:  A T Weil; W Davis
Journal:  J Ethnopharmacol       Date:  1994-01       Impact factor: 4.360

10.  Intensity of Mystical Experiences Occasioned by 5-MeO-DMT and Comparison With a Prior Psilocybin Study.

Authors:  Joseph Barsuglia; Alan K Davis; Robert Palmer; Rafael Lancelotta; Austin-Marley Windham-Herman; Kristel Peterson; Martin Polanco; Robert Grant; Roland R Griffiths
Journal:  Front Psychol       Date:  2018-12-06
View more
  5 in total

Review 1.  Predicting Reactions to Psychedelic Drugs: A Systematic Review of States and Traits Related to Acute Drug Effects.

Authors:  Jacob S Aday; Alan K Davis; Cayla M Mitzkovitz; Emily K Bloesch; Christopher C Davoli
Journal:  ACS Pharmacol Transl Sci       Date:  2021-03-05

2.  Synthesis and Characterization of 5-MeO-DMT Succinate for Clinical Use.

Authors:  Alexander M Sherwood; Romain Claveau; Rafael Lancelotta; Kristi W Kaylo; Kelsey Lenoch
Journal:  ACS Omega       Date:  2020-12-02

Review 3.  A narrative synthesis of research with 5-MeO-DMT.

Authors:  Anna O Ermakova; Fiona Dunbar; James Rucker; Matthew W Johnson
Journal:  J Psychopharmacol       Date:  2021-10-19       Impact factor: 4.153

Review 4.  Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders.

Authors:  Henry Lowe; Ngeh Toyang; Blair Steele; Justin Grant; Amza Ali; Lorenzo Gordon; Wilfred Ngwa
Journal:  Molecules       Date:  2022-04-14       Impact factor: 4.927

Review 5.  The clinical pharmacology and potential therapeutic applications of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT).

Authors:  Johannes T Reckweg; Malin V Uthaug; Attila Szabo; Alan K Davis; Rafael Lancelotta; Natasha L Mason; Johannes G Ramaekers
Journal:  J Neurochem       Date:  2022-03-08       Impact factor: 5.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.